Chemotherapy-Minimized Blank Microsphere Transarterial Embolization (BMS-TACE) in Hepatocellular Carcinoma Resistant to FOLFOX-Based Hepatic Arterial Infusion Chemotherapy
Chemotherapy-Minimized, Blank Microsphere-Based Transarterial Chemoembolization (BMS-TACE) in Patients With BCLC Stage B/C Hepatocellular Carcinoma Resistant to FOLFOX-Based Hepatic Arterial Infusion Chemotherapy: A Single-Center, Single-Arm, Phase 2 Trial
FOLFOX-based hepatic arterial infusion chemotherapy (HAIC) is widely used for advanced hepatocellular carcinoma (HCC) in China, yet many patients show primary resistance or progress after an initial response, and no prospective trial has defined the optimal salvage strategy. This single-center, single-arm, phase 2 trial evaluates the efficacy and safety of chemotherapy-minimized, blank microsphere-based transarterial chemoembolization (BMS-TACE) in patients with BCLC stage B/C HCC resistant to FOLFOX-HAIC. In BMS-TACE, blank microspheres are the principal embolic agent and chemotherapy is used only as an adjunct at a minimal dose (low-dose pirarubicin in a small volume of lipiodol), in order to limit chemotherapy-related liver injury and systemic toxicity and to allow repeated embolization in patients with limited hepatic reserve. Forty-three participants will be enrolled using a Simon two-stage design. The primary endpoint is objective response rate by investigator assessment using mRECIST.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Faza 2
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Jinhua Huang, MD, PhD
- Numer telefonu: 0086-20-87343447
- E-mail: huangjh@sysucc.org.cn
Lokalizacje studiów
-
-
Guangdong
-
Guangzhou, Guangdong, Chiny, 510060
- Rekrutacyjny
- Sun Yat-sen University Cancer Center
-
Kontakt:
- Jinhua Huang, MD, PhD
- Numer telefonu: 0086-20-87343447
- E-mail: huangjh@sysucc.org.cn
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Written informed consent
- Age 18-75 years, any sex
- Hepatocellular carcinoma confirmed by histology or cytology, or diagnosed clinically according to AASLD criteria
- BCLC stage C, or BCLC stage B beyond the up-to-seven criteria
- At least 4 prior cycles of FOLFOX-based hepatic arterial infusion chemotherapy (HAIC), with stable disease or progressive disease per RECIST 1.1 on contrast-enhanced CT or MRI performed 1-3 months after the last HAIC cycle
- Portal vein, hepatic vein or inferior vena cava tumor thrombus and distant metastasis are permitted
- Not a candidate for surgical resection as judged by the treating physician
- Child-Pugh score ≤ 7
- ECOG performance status 0-1
- Adequate bone marrow function: absolute neutrophil count ≥ 1.5 × 10^9/L; hemoglobin ≥ 70 g/L; platelet count ≥ 50 × 10^9/L; white blood cell count ≥ 3.0 × 10^9/L
- Adequate hepatic function: serum albumin ≥ 28 g/L; total bilirubin ≤ 3.0 mg/dL; AST and ALT ≤ 5 × upper limit of normal (ULN)
- Adequate renal function: serum creatinine ≤ 1.5 × ULN
- Adequate coagulation (not on anticoagulants): INR ≤ 2.3
- Active hepatitis B virus infection: on antiviral therapy per local standard of care and willing to continue during the study
- Hepatitis C virus antibody positive: on antiviral therapy per local standard of care and willing to continue during the study
Exclusion Criteria:
- History of hypersensitivity or intolerance to any agent used in the study
- Uncontrolled clinically significant ascites (not controlled by diuretics or paracentesis)
- History of hepatic encephalopathy
- Clinically significant gastrointestinal bleeding within 30 days before enrollment, or variceal bleeding within the past 3 months
- Uncorrectable coagulopathy or marked hematological abnormality with evident bleeding tendency
- Significant cardiovascular disease: congestive heart failure of NYHA class II or higher, unstable angina, myocardial infarction, or arrhythmia requiring medical treatment
- History of congenital long QT syndrome, or corrected QT interval > 480 ms (Fridericia)
- Left ventricular ejection fraction < 45%
- Inadequately controlled hypertension (systolic > 150 mmHg and/or diastolic > 100 mmHg)
- Urine protein ≥ 1 g/24 h (24-hour urine collection required if dipstick ≥ 1+)
- Prior organ transplantation
- Gastrointestinal malabsorption or any other condition that in the investigator's opinion may affect drug absorption
- Active infection other than HBV or HCV
- Other malignancy within the past 3 years or concurrent malignancy
- Any other condition that in the investigator's opinion makes the patient unsuitable for the study
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: BMS-TACE
All participants receive chemotherapy-minimized, blank microsphere-based transarterial chemoembolization (BMS-TACE). Retreatment is performed on demand according to imaging every 6 weeks until progression, unacceptable toxicity, technical infeasibility, or withdrawal. Participants who were receiving anti-angiogenic therapy plus a PD-1/PD-L1 inhibitor concurrently with FOLFOX-HAIC continue the same regimen unchanged; participants who received FOLFOX-HAIC without systemic therapy do not start systemic therapy during the study. Other locoregional treatments (ablation, seed implantation) are not permitted unless the tumor is downstaged to allow curative treatment. |
Visceral angiography of the celiac trunk, superior mesenteric artery and phrenic arteries maps the arterial supply of the tumor. A 2.8F microcatheter is placed super-selectively into each tumor-feeding artery by coaxial technique. A minimal-dose chemoemulsion (low-dose pirarubicin in a small volume of lipiodol) is injected first. Blank microspheres of any manufacturer are then delivered in ascending size order: 40-120 microns mixed with 5 mL contrast to occlude the distal tumor arterial bed; 100-300 microns for tumor arterial branches, with supplementary lipiodol emulsion if vascular lakes are seen; then 300-500 or 500-700 microns for the main feeding trunk. The endpoint is contrast stasis over 3-5 cardiac cycles with loss of at least 90% of intrahepatic tumor staining on completion angiography. Imaging is repeated every 6 weeks; retreatment follows protocol-defined criteria. Performed by one of two designated interventional radiologists.
Inne nazwy:
Low-dose pirarubicin emulsified with a small volume of lipiodol and injected intra-arterially into the tumor-feeding artery immediately before blank microsphere embolization, as the minimal-dose chemotherapy adjunct of each BMS-TACE session.
Inne nazwy:
Calibrated blank (non-drug-loaded) microspheres, 40-120, 100-300, 300-500 and 500-700 microns, of any manufacturer, delivered in ascending size order as the principal embolic agent in BMS-TACE. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Objective Response Rate (ORR) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST) as Assessed by Investigator
Ramy czasowe: From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)
|
ORR is defined as the proportion of participants whose best overall response from enrollment (first BMS-TACE) is complete response (CR) or partial response (PR) per mRECIST, as assessed by the investigator together with a senior radiologist. Tumor assessment by contrast-enhanced CT or MRI is performed after the first BMS-TACE and every 6 weeks (±7 days) thereafter, regardless of treatment delays, until progression, unacceptable toxicity, death, withdrawal of consent, loss to follow-up or study termination. Analysis population: full analysis set (all enrolled participants); participants without post-baseline assessment are counted as non-responders. |
From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Progression-Free Survival (PFS) Per mRECIST as Assessed by Investigator
Ramy czasowe: From enrollment until progression or death (up to approximately 30 months)
|
PFS is defined as the time from enrollment (first BMS-TACE) to the first documented radiological progression per mRECIST or death from any cause, whichever occurs first. Participants alive without progression are censored at the date of last tumor assessment. Estimated by the Kaplan-Meier method. |
From enrollment until progression or death (up to approximately 30 months)
|
|
Disease Control Rate (DCR) Per mRECIST as Assessed by Investigator
Ramy czasowe: From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)
|
Proportion of participants whose best overall response is CR, PR or stable disease (SD) per mRECIST, using the same assessment schedule as the primary outcome. |
From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)
|
|
Duration of Response (DOR) Per mRECIST as Assessed by Investigator
Ramy czasowe: From first documented response until progression or death (up to approximately 30 months)
|
Among responders, the time from first documented CR or PR to first documented progression per mRECIST or death from any cause, whichever occurs first; responders without progression or death are censored at the last tumor assessment. |
From first documented response until progression or death (up to approximately 30 months)
|
|
Overall Survival (OS)
Ramy czasowe: From enrollment until death from any cause (up to approximately 30 months)
|
OS is defined as the time from enrollment to death from any cause. Participants alive at last contact are censored at the date of last follow-up. Survival follow-up every 12 weeks (±7 days) after progression or start of new anticancer therapy, continuing until at least 12 months after the last participant's first BMS-TACE. |
From enrollment until death from any cause (up to approximately 30 months)
|
|
Time to Untreatable Progression (TTUP)
Ramy czasowe: From enrollment until untreatable progression (up to approximately 30 months)
|
Time from enrollment to progression that precludes further BMS-TACE, including untreatable tumor progression and deterioration of liver function to Child-Pugh class C, as judged by the investigator. Participants still eligible for BMS-TACE are censored at last assessment. |
From enrollment until untreatable progression (up to approximately 30 months)
|
|
Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by Investigator
Ramy czasowe: From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)
|
Sensitivity analysis of the primary endpoint: proportion of participants with best overall response of CR or PR per RECIST 1.1, using the same assessment schedule. |
From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)
|
|
Incidence and Severity of Adverse Events Per NCI CTCAE Version 5.0
Ramy czasowe: From first BMS-TACE until 30 days after last BMS-TACE (up to approximately 13 months)
|
Number and proportion of participants with treatment-emergent adverse events, serious adverse events and treatment-related adverse events, graded per NCI CTCAE v5.0, from first BMS-TACE until 30 days after the last BMS-TACE or start of new anticancer therapy, whichever is first. Safety set: all participants who receive at least one BMS-TACE. |
From first BMS-TACE until 30 days after last BMS-TACE (up to approximately 13 months)
|
Inne miary wyników
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change From Baseline in Quality of Life Per EORTC QLQ-C30
Ramy czasowe: Baseline, every 6 weeks during treatment, and end of treatment (up to approximately 12 months)
|
Change from baseline in health-related quality of life assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Scores for the global health status/quality of life scale, the five functional scales, and the symptom scales/items are linearly transformed to range from 0 to 100. Higher global health status/quality of life and functional scores indicate better quality of life or functioning; higher symptom scores indicate worse symptoms/problems. Change from baseline is calculated separately for each scale/item as the post-baseline score minus the baseline score. |
Baseline, every 6 weeks during treatment, and end of treatment (up to approximately 12 months)
|
|
Change From Baseline in Quality of Life Per EORTC QLQ-HCC18
Ramy czasowe: Baseline, every 6 weeks during treatment, and end of treatment (up to approximately 12 months)
|
Change from baseline assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Hepatocellular Carcinoma Module (EORTC QLQ-HCC18). This 18-item module assesses fatigue, body image, jaundice, nutrition, pain, fever, abdominal swelling, and sexual interest. Each scale/item score is linearly transformed to range from 0 to 100; higher scores indicate worse symptoms/problems or poorer health-related quality of life. Change from baseline is calculated separately for each scale/item as the post-baseline score minus the baseline score. |
Baseline, every 6 weeks during treatment, and end of treatment (up to approximately 12 months)
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Główny śledczy: Jinhua Huang, MD, PhD, Sun Yat-Sen University Cancer Center
- Dyrektor Studium: Zhimei Huang, MD, Sun Yat-Sen University Cancer Center
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- SL-B2025-858-02
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .